ADX-914

· Q32 Bio Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ADX-914, covering 2024-10-03 to 2024-10-03. Get the full timeline:

Most recent: Clinical Trial Update: Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) [Phase 2]

See pricing